Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab combined with intravesical BCG for high-risk BCG-naive NMIBC
ChiCTR2500100281Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Sichuan Cancer Hospital. Primary endpoint: Recurrence-free survival. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
serplulimabbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2500100281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100281.